VKTX Latest Headlines

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Rockwell Med (RMTI) and Inhibikase Therapeutics (IKT)

at www.tipranks.com (Fri, 27-Mar 9:10 AM)

VKTX Hits Milestone: VK2735 Phase 3 Obesity and Diabetes Trial Completes Enrollment Ahead of Key 2026 Data

Market Chameleon (Thu, 26-Mar 8:57 AM)

Viking Therapeutics: Accelerated VK2735 Obesity Program and Single-Molecule Strategy Support Buy Rating and Favorable Risk-Reward

at www.tipranks.com (Thu, 26-Mar 10:45 AM)

Strong Enrollment and Phase 3 Momentum Underpin Buy Rating on Viking Therapeutics’ Obesity Program

at www.tipranks.com (Thu, 26-Mar 9:25 AM)

Viking Therapeutics Highlights Clinical Momentum Ahead of Key Investor Conferences

Market Chameleon (Fri, 6-Mar 9:12 AM)

VKTX's Obesity Drug Pipeline Shines: Phase 3 Progress, Weight Loss Data, and a Strong Cash Position Define 2025

Market Chameleon (Thu, 12-Feb 11:12 AM)

Viking Therapeutics Sets Date for Crucial 2025 Results Amid Progress in Obesity and Liver Disease Programs

Market Chameleon (Thu, 5-Feb 8:39 AM)

VK2735 Shows Up to 14.7% Weight Loss in Phase 2, No Plateau Observed—Phase 3 Now Underway

Market Chameleon (Mon, 12-Jan 8:21 AM)